NeuroSearch Sweden AB: Next Steps to Treat Parkinson's, Huntington's and Alzheimer's Disease

Joachim Tedroff, Head of Clinical Science at NeuroSearch Sweden AB, joined Pharma IQ to discuss Optimising Clinical Development in CNS. He discussed compound ACR16 or pridopidine, which is a generic name, that was developed in Carlsson Research about ten years ago. It belongs to a new class of compounds called dopidines which are developed from an in vivo screening method. End Quote

(1888PressRelease) January 25, 2011 - Carlsson Research started with the hypothesis that there is no target but rather you have to change the way the brain works, the system, the connectivity of the various brain areas associated with Huntingdon's disease.

''What we've found out is these compounds that can modulate dopamine transmission but also strengthen glutamartology transmission could be beneficial in Huntingdon's disease and there are actually two trials now showing essentially the same thing, the Phase Three MermaiHD study and the Phase 2B study in the US called the HART study, so we are very encouraged with these results and this is actually the first time a drug ever affects key or core Huntingdon's disease symptoms'' says Tedroff.

You can download the full interview from http://bit.ly/e98SzD

The interview has been conducted in relation to Pharma IQ's Optimising Clinical Development in CNS event, taking place 15 - 16 March, 2011 in London. The event is co-located with 2nd Annual Optimising Clinical Development in Oncology as a part of Clinical Trials Summit.

For more information, please visit www.clinicalcns.com, email enquire ( @ ) iqpc dot co.uk or call 44 (0) 2073679300

###

space

Other Related Press Releases